title: Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone.
abstract: Outcome for the vast majority of high-risk neuroblastoma patients with refractory or relapsed disease is dismal. We report two high-risk patients who remain progression-free for more than 113 and 18 months following the diagnosis of refractory/relapsed disease who were treated with surgery alone. Complete resolution of a refractory thoracic mass and relapsed liver nodules was observed in one patient. The refractory/relapsed disease in the second patient has remained stable. In both cases, the tumor showed histologic evidence of neuroblastoma maturation. These cases demonstrate that refractory/relapsed neuroblastoma is clinically heterogeneous and highlight the need for better biomarkers to optimize patient care.
authors.affiliation: Department of Pediatrics, University of Chicago, Chicago, Illinois 60637, USA. scohn@peds.bsd.uchicago.edu
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Sokol
authors.forename: Paul R
authors.initials: PR
authors.lastname: Haut
authors.forename: Yasmin
authors.initials: Y
authors.lastname: Gosiengfiao
authors.forename: Kate
authors.initials: K
authors.lastname: Feinstein
authors.forename: Peter
authors.initials: P
authors.lastname: Pytel
authors.forename: Susan L
authors.initials: SL
authors.lastname: Cohn
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000601:surgery*; D009447:Neuroblastoma / Q000401:mortality* / Q000601:surgery*; D033581:Stem Cell Transplantation